During the past decade, Care Access Research-Walnut Creek conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 15 clinical trials were completed, i.e. on average, 57.7% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 15 clinical trials were completed. i.e. 136.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Care Access Research-Walnut Creek" #1 sponsor was "Eli Lilly and Company" with 17 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "Allergan" with 1 trials sponsored and "Amgen" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Care Access Research-Walnut Creek" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator, "AbCellera Biologics Inc." with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials as a collaborator and "Shanghai Junshi Bioscience Co., Ltd." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Care Access Research-Walnut Creek" are "Crohn's Disease" (4 trials), "Ulcerative Colitis" (4 trials), "Atopic Dermatitis" (2 trials), "Axial Spondyloarthritis" (2 trials) and "Psoriasis" (2 trials). Many other conditions were trialed in "Care Access Research-Walnut Creek" in a lesser frequency.

Most popular intervention types in "Care Access Research-Walnut Creek" are "Drug" (25 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Guselkumab" (5 trials), "Ixekizumab" (5 trials), "Mirikizumab" (4 trials) and "BMS-986165" (2 trials). Other intervention names were less common.

The vast majority of trials in "Care Access Research-Walnut Creek" are 25 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Care Access Research-Walnut Creek". undefined are not yet recruiting, 7 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Care Access Research-Walnut Creek, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Care Access Research-Walnut Creek, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".